AMPE, PNK

Ampio Pharmaceuticals, Inc. (AMPE)

Price (as of October 25)

0.0311USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

DICE

DICE Therapeutics, Inc.

-0.34

PYXS

Pyxis Oncology, Inc.

-0.11

LVTX

LAVA Therapeutics N.V.

-0.11

XLO

Xilio Therapeutics, Inc.

-0.1

BCAB

BioAtla, Inc.

-0.09

PHAR

Pharming Group N.V.

-0.09

TCBP

TC Biopharm (Holdings) Plc

-0.09

PHVS

Pharvaris N.V.

-0.08

NVCT

Nuvectis Pharma, Inc.

-0.08

ICVX

Icosavax, Inc.

-0.07

Show more

Highest within Industry

Symbol Correlation

ATAI

Atai Life Sciences N.V.

0.17

PEPG

PepGen Inc.

0.16

IMRX

Immuneering Corporation

0.14

RNA

Avidity Biosciences, Inc.

0.12

NUVL

Nuvalent, Inc.

0.11

EQRXW

EQRx, Inc.

0.1

ALLO

Allogene Therapeutics, Inc.

0.1

RCOR

Renovacor, Inc.

0.1

GLUE

Monte Rosa Therapeutics, Inc.

0.1

MOLN

Molecular Partners AG

0.1

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.